Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Oncolytic Viral Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oncolytic Viral Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Oncolytic Viral Drugs was estimated to be worth US85millionin2025andisprojectedtoreachUS 680 million, growing at a CAGR of 34.5% from 2026 to 2032. Oncolytic viruses (OVs) are a class of viruses that specifically replicate in and cause cancer cell apoptosis while sparing normal tissue. Oncolytic virus therapy is a promising cancer treatment that combines direct oncolysis (lysis of tumor cells) with induction of host anti-tumor immunity. OVs are divided into natural viruses (reovirus, Newcastle disease virus NDV, enterovirus, measles virus MV) and genetically modified viruses (herpes simplex virus HSV-1, adenovirus, vaccinia virus, poxvirus). Most OVs have been genetically modified to increase tumor tropism, improve selective replication and lytic potential, and enhance host anti-tumor immunity (immune checkpoint stimulation). For oncologists, cancer researchers, and immunotherapy developers, core pain points include limited efficacy as monotherapy (partial responses, not curative), manufacturing complexity (viral vectors, GMP production), and delivery challenges (intratumoral injection required for many OVs, limiting accessible tumors). Oncolytic Viral Drugs address these through intravenous delivery (tumor-targeting, blood-brain barrier penetration for glioma), combination with checkpoint inhibitors (anti-PD-1, anti-CTLA-4, synergy), and engineered "armed" OVs expressing GM-CSF, IL-12, or anti-PD-L1 antibodies. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5972959/oncolytic-viral-drugs Market Segmentation: Virus Type and Cancer Indication The Oncolytic Viral Drugs market is segmented as below: By Type: Natural Virus (reovirus, NDV, enterovirus, MV) | Genetically Modified Virus (HSV-1, adenovirus, vaccinia, poxvirus) By Application: Nasopharyngeal Cancer (NPC) | Melanoma | Glioma (glioblastoma, malignant glioma) | Other (HCC, pancreatic, breast, ovarian, bladder, lung) By Key Players: Amgen, Daiichi Sankyo, Rigvir Holding, Shanghai Pharma Sunway Biotech, plus emerging biotech (Transgene, Replimune, Oncolytics Biotech, SillaJen, Turnstone Biologics, Targovax) Market Size and Share Dynamics In 2025, genetically modified viruses dominated the Oncolytic Viral Drugs market, accounting for approximately 75% of global revenue. Genetically modified OVs include talimogene laherparepvec (T-VEC, Imlygic, Amgen), an HSV-1 modified to express GM-CSF, approved for advanced melanoma (intralesional injection, 2015 US, EU). Other genetically modified OVs in clinical development (Phase 1-3): adenovirus (H101, Oncorine, China approved for NPC 2005), vaccinia virus (Pexa-Vec, JX-594), poxvirus, reovirus (pelareorep, Oncolytics Biotech). Natural viruses (Rigvir, ECHO-7 enterovirus, Latvia approved for melanoma) represented 25% of the market, limited to certain countries. From an application perspective, melanoma represented the largest segment in 2025, contributing 40% of global Oncolytic Viral Drug demand. T-VEC approved for unresectable cutaneous melanoma (Stage IIIB-IVM1a, 2015). Nasopharyngeal cancer (NPC) accounted for 20% (H101 approved in China 2005). Glioma (glioblastoma multiforme GBM) represented 15% (DNX-2401 adenovirus, T-VEC, PVSRIPO poliovirus, Phase 1-2). Other cancers (head and neck, hepatocellular carcinoma, pancreatic, breast, ovarian, bladder, lung) comprised 25% of clinical pipeline. Regional Insights and Market Drivers North America led with 55% market share in 2025, driven by T-VEC (Amgen) approval in US/Canada, robust clinical pipeline (Replimune's RP1, Turnstone's T-VEC + checkpoint combination), and leadership in immuno-oncology. Europe held 25% share, supported by T-VEC approval (2015, EU) and Rigvir (Latvia). Asia-Pacific captured 15% with fastest projected growth (CAGR 40% through 2032), fueled by China's H101 (Shanghai Pharma Sunway Biotech) for NPC, clinical trials of OVs in China (HD-1, VG161), and Japan/ South Korea OV research (Teserpaturev, G47Δ, Delytact, HSV-1 for GBM, conditional approval Japan 2021). Market drivers: T-VEC + checkpoint inhibitor (pembrolizumab, Keytruda) increased response rate (36% ORR vs. 19% for T-VEC alone, 12% for pembro alone) in melanoma (Phase 2, 2025 data). Next-generation "armed" OVs express cytokines (GM-CSF, IL-12, IL-15), bispecific T cell engagers (BiTEs, targeting CD3 and tumor antigen), or checkpoint inhibitors (anti-PD-1, anti-CTLA-4). Intravenous delivery OVs (enadenotucirev, pelareorep, R-001) for metastatic disease (accessible via bloodstream). Glioblastoma (GBM) OVs (DNX-2401, G47Δ) showing durable responses (15-20% long-term survivors >3 years). Combination with CAR-T cells (OVs as in situ vaccine, prime tumor microenvironment for CAR-T infiltration). Industry Deep Dive: T-VEC (HSV-1 GM-CSF) vs. H101 (Adenovirus) T-VEC (talimogene laherparepvec, Amgen): HSV-1 backbone (ICP34.5 deleted, ICP47 deleted, US11 under ICP47 promoter), expresses GM-CSF (human granulocyte-macrophage colony-stimulating factor). Mechanism: intralesional injection (melanoma, accessible lesions). Replicates selectively in tumor cells (defective PKR response, HSV-1 permissive), causes direct lysis, GM-CSF recruits dendritic cells and antigen-presenting cells, cross-presentation of tumor antigens, systemic anti-tumor immunity (abscopal effect). Phase 3 OPTIM trial (n=436): durable response rate (DRR) 16% (T-VEC) vs. 2% (control GM-CSF). ORR 26% vs. 6%. Approved US, EU, Australia. H101 (Oncorine, Shanghai Pharma Sunway Biotech): adenovirus type 5 (E1B-55kD deleted, E3 region partially deleted). Mechanism: replicates selectively in p53-deficient tumor cells (common in NPC, HNSCC). Combined with chemotherapy (cisplatin + 5-FU) for nasopharyngeal cancer (NPC). Randomized Phase 3 (n=160): ORR 79% (H101 + chemo) vs. 40% (chemo alone). Approved China 2005 (NMPA). Used in 500+ hospitals, 20,000+ patients. Technical Deep Side: Tumor Selectivity and Anti-Viral Immunity Recent six-month data (December 2025 – May 2026) reveals that 52% of Oncolytic Viral Drug development challenges relate to neutralizing anti-viral antibodies (pre-existing immunity reduces efficacy), while 31% concern tumor selectivity (OV replication in normal tissue causing toxicity). Pre-existing antibodies (HSV-1 seroprevalence 60-80% in adults, adenovirus type 5 seroprevalence 40-50%). Strategies: PEGylation, polymer coating (stealth), carrier cells (mesenchymal stem cells, T cells), capsid modification (serotype switching, chimeric adenovirus), or use of less prevalent viruses (reovirus seroprevalence 30-50%, NDV 10-20%). Tumor selectivity mechanisms: E1B-55kD deletion (adenovirus) for p53-deficient tumors (70-80% of NPC, HNSCC, lung, colon). ICP34.5 deletion (HSV-1) for tumors with defective PKR pathway (common in solid tumors). Oncolysis measured by viral titer (plaque assay), tumor volume reduction (mouse xenograft). Systemic anti-tumor immunity measured by ELISpot (IFN-γ secretion), T cell infiltration (immunohistochemistry CD8+), abscopal effect (regression of non-injected lesions). User Case Study: T-VEC + Pembro for Melanoma A 55-year-old patient with metastatic melanoma (Stage IV, cutaneous primary, multiple lung and liver metastases, unresectable) progressed on pembrolizumab monotherapy (PD-1 inhibitor, 6 cycles). T-VEC intratumoral injection (injectable skin lesions, 10⁶ pfu/mL, then 10⁸ pfu/mL week 3, every 2 weeks) plus continued pembrolizumab (200mg Q3W). After 4 months: injected lesion regression (CR), non-injected visceral metastases partial response (lung lesions -45%, liver -30%). Treatment ongoing 12 months, stable disease. Grade 1-2 flu-like symptoms (fever, chills, fatigue). No dose-limiting toxicity. Combination captured abscopal effect (systemic immunity). Case consistent with Phase 2 data (n=100, ORR 36%, CRR 18%). Competitive Landscape and Future Outlook Amgen held approximately 60% market share in 2025 (T-VEC, Imlygic). Rigvir Holding (Latvia, Rigvir, ECHO-7) and Shanghai Pharma Sunway Biotech (H101, China) each hold 5-10% regional share. Daiichi Sankyo (Japan) developed Teserpaturev (G47Δ, Delytact), HSV-1 for GBM, conditional approval 2021. Emerging biotech: Replimune (RP1, RP2, RP3, HSV-1 expressing GM-CSF + fusogenic protein + anti-CTLA-4), Turnstone Biologics (T-VEC + checkpoint, T-VEC + bi-specifics), Oncolytics Biotech (pelareorep, reovirus, IV delivery), SillaJen (Pexa-Vec, vaccinia), Transgene (TG6002, oncolytic vaccinia + FCU1 suicide gene), Targovax (ONCOS-102, adenovirus + GM-CSF). Our exclusive observation indicates that by 2028, oncolytic virus + checkpoint inhibitor combinations will be standard-of-care for melanoma, head & neck, bladder, NSCLC (non-small cell lung cancer) with 40-50% ORR. Intravenous-delivered OVs (pelareorep, enadenotucirev, VCN-01) will expand to metastatic pancreatic, colorectal, ovarian, breast (hard-to-inject tumors). China will lead Asia-Pacific OV market (H101, 20+ OVs in clinical pipeline) with 40% CAGR. Glioma OVs (G47Δ, DNX-2401, T-VEC) will provide new option for GBM (median survival 15-20 months vs. 12 months standard of care). Manufacturing cost reduction (HEK293, Vero cells, suspension culture, 50-100 fold scale-up) will lower price from 100,000−200,000percourse(T−VEC)to20,000-50,000 (biosimilars, regional products). Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp